Chemomab Completes CM-101 PSC Trial Enrollment, Topline Data Mid-2024
Ticker: CMMB · Form: 6-K · Filed: Jan 3, 2024 · CIK: 1534248
| Field | Detail |
|---|---|
| Company | Chemomab Therapeutics LTD. (CMMB) |
| Form Type | 6-K |
| Filed Date | Jan 3, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: clinical-trial, drug-development, biotechnology, regulatory-filing
TL;DR
**Chemomab finished CM-101 trial enrollment, expecting key data by mid-2024, watch for big stock moves.**
AI Summary
Chemomab Therapeutics Ltd. announced on January 3, 2024, the successful completion of patient enrollment for its CM-101 Phase 2 clinical trial targeting Primary Sclerosing Cholangitis (PSC). This significant milestone means the company now expects to release the crucial 'topline readout' data for this trial by mid-2024, earlier than previously anticipated. This acceleration is important for investors because positive results could significantly boost the stock price, while negative results could cause a decline, as the drug's potential is a key driver of the company's valuation.
Why It Matters
Completing patient enrollment and accelerating the data readout for a key drug candidate like CM-101 reduces uncertainty and brings the company closer to a major value-inflection point, directly impacting investor sentiment and stock valuation.
Risk Assessment
Risk Level: medium — While completing enrollment is positive, the stock's future still heavily depends on the actual clinical trial results, which carry inherent risks in drug development.
Analyst Insight
An investor should monitor Chemomab Therapeutics closely as mid-2024 approaches, as the CM-101 trial results will be a major catalyst. Consider setting alerts for the announcement and reviewing the data carefully for its implications on the drug's path to market.
Key Players & Entities
- Chemomab Therapeutics Ltd. (company) — the registrant filing the 6-K
- CM-101 (drug) — the drug candidate in Phase 2 trial
- Primary Sclerosing Cholangitis (disease) — the condition CM-101 is being tested for
- Sigal Fattal (person) — signed the 6-K report on behalf of Chemomab
- January 3, 2024 (date) — date of the press release and 6-K filing
- mid-2024 (date) — new expected timeframe for topline readout
Forward-Looking Statements
- Chemomab's stock price will experience significant volatility around mid-2024. (Chemomab Therapeutics Ltd.) — high confidence, target: mid-2024
- Positive topline results for CM-101 will lead to a substantial increase in Chemomab's market capitalization. (Chemomab Therapeutics Ltd.) — medium confidence, target: mid-2024
FAQ
What is the primary purpose of this 6-K filing by Chemomab Therapeutics Ltd.?
The primary purpose of this 6-K filing is to furnish a press release, dated January 3, 2024, announcing the completion of patient enrollment in the CM-101 Phase 2 Primary Sclerosing Cholangitis trial and the accelerated expected topline readout to mid-2024.
Which specific drug candidate and disease are mentioned in the press release furnished by Chemomab Therapeutics Ltd.?
The press release specifically mentions the drug candidate CM-101 and the disease Primary Sclerosing Cholangitis (PSC).
When is Chemomab Therapeutics Ltd. now expecting the topline readout for the CM-101 Phase 2 trial?
Chemomab Therapeutics Ltd. is now expecting the topline readout for the CM-101 Phase 2 trial to be by mid-2024, which is an accelerated timeline.
Into which of the Company's Registration Statements is Exhibit 99.1 of this 6-K incorporated by reference?
Exhibit 99.1 is incorporated by reference into the Company's Registration Statements on Form F-3 (File No. 333-275002) and Form S-8 (File No. 333-259489 and No. 333-266868).
Who signed the 6-K report on behalf of Chemomab Therapeutics Ltd. and on what date?
The 6-K report was signed by Sigal Fattal on behalf of Chemomab Therapeutics Ltd. on January 3, 2024.
Filing Stats: 262 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2024-01-03 07:00:16
Filing Documents
- zk2430725.htm (6-K) — 11KB
- exhibit_99-1.htm (EX-99.1) — 14KB
- image00002.jpg (GRAPHIC) — 21KB
- 0001178913-24-000033.txt ( ) — 55KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant's name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE This Report of Foreign Private Issuer on Form 6-K (the "Form 6-K") is being furnished by Chemomab Therapeutics Ltd. (the "Company") for the purpose of furnishing, as Exhibit 99.1 to this Form 6-K, a press release, dated January 3, 2024, titled "Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024". Exhibit 99.1 to this Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form F-3 (File No. 333-275002) and Form S-8 (File No. 333-259489 and No. 333-266868). EXHIBIT INDEX Exhibit Description 99.1 Press release, dated January 3, 2024, titled "Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024" SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CHEMOMAB THERAPEUTICS LTD. Date: January 3, 2024 By: /s/ Sigal Fattal Sigal Fattal Chief Financial Officer